INB-03 Drug Asset Due Diligence Report 2026

This INB-03 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether INB-03 can convert its Tumor necrosis factors profile and TNF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	INB-03 (query alias: INB-03)
Modality / target	Tumor necrosis factors; TNF; TNF inhibitors
Highest global status	Phase 2
Originator	Xencor, Inc.
Active developers	INmune Bio, Inc.

The MCP disease footprint includes Alzheimer Disease, Inflammation, Mild cognitive disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05522387	Phase 2	Terminated	11	Primary endpoint not disclosed in English source
NCT05321498	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source
NCT05318976	Phase 2	Completed	207	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Phase 2; n=207; evaluation: Not stated in English source. Reported fields: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)(LS Mean) = 0.05 Z-score ; Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)(LS Mean) = 0.07 Z-score

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)

Phase 2/3; n=79; evaluation: Not stated in English source. Reported fields: Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression = 10 Pts ; Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression = 6 Pts

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

Phase 2; n=208; evaluation: Positive. Reported fields: EMACC(mITT group) = was not met Not Met; EMACC(mITT group) = was not met Not Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

INB-03 addresses Alzheimer Disease, Inflammation, Mild cognitive disorder. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Tumor necrosis factors—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-10-03	INmune Bio, Inc.announces that it has licensed INB03	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Stabilized DN-TNF mutein bioconjugates for selective soluble TNF neutralization”. The milestone feed surfaced a patent-application signal described as “Compositions & method of treating epilepsy by selective sequestration of soluble TNF”. The milestone feed surfaced a patent-application signal described as “Bioconjugates of dominant negative TNF”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO